Canagliflozin_842133-18-0_DataSheet_MedChemExpress

Product Data SheetProduct Name:CAS No.: Cat. No.:MWt:Formula:Purity :Canagliflozin842133-18-0HY-10451444.52C24H25FO5S>98%Solubility:DMSO ≥85mg/mL Water<1.2mg/mL Ethanol ≥85mg/mLMechanisms: Pathways:GPCR/G protein; Target:SGLT2 Pathways:Membrane Transporter/Ion Channel; Target:SGLT2 gyBiological Activity:Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an experimentaldrug being developed by Johnson & Johnson for the treatment of type 2 diabetes.Canagliflozin(JNJ24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorptionin the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.References:[1]. Sumihiro Nomura et al. Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, asSodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes MellitusJ. Med. Chem., 2010, 53 (17), pp 6355-6360 [][2]. Nicolle LE, Capuano G, Ways K, Usiskin K.pyEffect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria andurinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin. 2012 Jul;28(7):1167-71. [3]. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W;Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on tometformin in subjects with type 2 diabetes. Diabetes Care. 2012 Jun;35(6):1232-8. [4]LiYAkKUt[4]. Liang Y, Arakawa K, Ueta ...Caution: Not fully tested. For research purposes onlyMedchemexpress LLCwww.medchemexpress.com18Wilkinson Way, Princeton, NJ 08540,USAEmail: info@medchemexpress.com Web: www.medchemexpress.com